Health Care & Life Sciences » Pharmaceuticals | Pharmesis International Ltd.

Pharmesis International Ltd. | Balance Sheet

Fiscal year is January-December. All values SGD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,914.80
10,960.50
16,853.40
9,325.10
7,282.30
6,891.70
Total Accounts Receivable
6,978.00
6,315.20
4,990.00
11,583.20
6,995.80
6,782.30
Inventories
1,199.00
1,153.80
1,475.80
1,489.90
1,485.60
1,930.60
Other Current Assets
50.30
67.10
159.00
90.60
282.00
33.20
Total Current Assets
16,142.10
18,496.50
23,478.20
22,488.80
16,045.60
15,637.90
Net Property, Plant & Equipment
3,183.00
2,926.80
2,876.40
2,357.00
7,655.20
8,056.90
Intangible Assets
1,204.60
282.60
289.00
275.00
271.50
262.60
Other Assets
657.40
651.70
644.50
592.30
1,619.60
1,512.80
Total Assets
21,187.20
22,357.50
27,288.10
25,713.10
25,591.90
25,470.10
ST Debt & Current Portion LT Debt
-
1,067.90
3,277.00
3,118.30
3,078.30
Accounts Payable
371.90
433.20
640.10
786.20
391.40
Income Tax Payable
2.10
4.50
137.60
369.60
48.20
Other Current Liabilities
689.10
1,233.50
1,085.40
1,414.00
2,680.40
Total Current Liabilities
1,063.00
2,739.10
5,140.10
5,688.20
6,198.30
Deferred Taxes
101.80
104.20
106.60
101.40
100.10
Total Liabilities
1,164.80
2,843.30
5,246.80
5,789.60
6,298.40
Common Equity (Total)
19,004.60
18,650.10
21,009.30
19,026.90
18,274.70
Total Shareholders' Equity
19,004.60
18,650.10
21,009.30
19,026.90
18,274.70
Total Equity
20,022.40
19,514.30
22,041.30
19,923.50
19,293.50
Liabilities & Shareholders' Equity
21,187.20
22,357.50
27,288.10
25,713.10
25,591.90
Accumulated Minority Interest
1,017.80
864.20
1,032.00
896.60
1,018.70

About Pharmesis International

View Profile
Address
No. 8 Yingbin Road
Chengdu Sichuan 611331
China
Employees -
Website http://www.pharmesis.com
Updated 07/08/2019
Pharmesis International Ltd. Is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates through the following segments: Western Drugs, Traditional Chinese Medicine (TCM) Formulated Drugs, and Distribution. The Western Drugs segment involves in the chemically formulated drugs and is marketed under the Kinna brand.